Stopping the spread of lung cancer in patients with a specific gene change
Targeting the ROR2/p-GSK3bS9 pathway to suppress metastasis in SMARCA4-deficient lung adenocarcinoma
This research aims to find new ways to prevent lung cancer from spreading in patients who have a particular genetic change called SMARCA4 deficiency.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11129917 on NIH RePORTER |
What this research studies
Many people with lung cancer face the challenge of the disease spreading to other parts of the body, which is a major cause of death. This project focuses on a specific type of lung cancer, adenocarcinoma, where a gene called SMARCA4 is often changed. When SMARCA4 is altered, it can make the cancer more likely to spread. Our team is exploring a new biological pathway, involving ROR2 and GSK3βS9, that seems to drive this spread in SMARCA4-deficient lung cancer. By understanding and targeting this pathway, we hope to develop new treatments that can stop the cancer from spreading.
Who could benefit from this research
Good fit: This research is most relevant to patients diagnosed with lung adenocarcinoma, particularly those whose tumors have a SMARCA4 gene deficiency.
Not a fit: Patients with lung cancer types other than adenocarcinoma or those without SMARCA4 deficiency may not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that prevent or reduce the spread of lung adenocarcinoma, especially for patients with SMARCA4 gene changes.
How similar studies have performed: While the general concept of targeting cancer pathways is established, this specific approach of targeting the ROR2/p-GSK3βS9 pathway in SMARCA4-deficient lung adenocarcinoma is a novel area of investigation.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Jones, David R — Sloan-Kettering Inst Can Research
- Study coordinator: Jones, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.